News
VOR
19.88
+6.54%
1.22
Vor Biopharma (VOR) Cut Quarterly Losses, Is The Stock Still Below Fair Value?
Simply Wall St · 2h ago
Weekly Report: what happened at VOR last week (1102-1106)?
Weekly Report · 6h ago
Late Stage Trial Progress Could Change The Case For Vor Biopharma Stock
Simply Wall St · 1d ago
Vor Biopharma (VOR) Stock May Look Reasonable On Telitacicept Trial Progress
Simply Wall St · 6d ago
Robert W. Baird Remains a Buy on Vor Biopharma (VOR)
TipRanks · 6d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 6d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Vor Biopharma (VOR)
TipRanks · 6d ago
Weekly Report: what happened at VOR last week (1026-1030)?
Weekly Report · 11/02 09:07
Is Vor Biopharma (VOR) Undervalued Following Phase 3 Progress And A $150 Million Equity Plan?
Simply Wall St · 11/01 22:22
Vor Biopharma Stock Gets A Lift From Kidney Disease Trial Results
Simply Wall St · 10/31 09:36
Vor Biopharma Files Prospectus For Offering $150M Common Shares
Benzinga · 10/30 12:50
Vor Biopharma reports Q3 results
Seeking Alpha · 10/30 12:18
*Vor Biopharma 3Q Research and Development Expenses $34.5M >VOR
Dow Jones · 10/30 12:01
Press Release: Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 10/30 12:00
Weekly Report: what happened at VOR last week (1019-1023)?
Weekly Report · 10/26 09:07
Vor Biopharma (VOR) After TELIGAN Data Has An Undervalued Narrative Back In Focus
Simply Wall St · 10/24 22:30
Learn Why The Bull Case For Vor Biopharma Stock Could Change Following Phase 3 Kidney Trial Results
Simply Wall St · 10/23 15:42
Vor Bio’s telitacicept meets primary endpoint in Phase 3 kidney trial
TipRanks · 10/22 20:50
Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropathy; TELIGAN Met Stage B Primary Endpoint
Benzinga · 10/22 20:09
Vor Biopharma Initiated at Outperform by William Blair
Dow Jones · 10/21 12:47
More
Webull provides a variety of real-time VOR stock news. You can receive the latest news about Vor Biopharma Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VOR
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.